A study of morphine-induced urinary retention in anesthetized rats capable of micturition

H Kontani1, Y Kawabata

  • 1Department of Pharmacology, Hokuriku University, School of Pharmacy, Kanazawa, Japan.

Insights

Morphine causes urinary retention by inhibiting bladder contractions through opioid receptors in the brain and spinal cord. Naloxone, an opioid antagonist, reverses this effect, indicating a central mechanism of action.

Area of Science:

  • Neuropharmacology
  • Urology
  • Physiology

Background:

  • Opioid analgesics like morphine are known to cause urinary retention, a common side effect.
  • The precise mechanisms underlying morphine-induced urinary retention are not fully understood.
  • Understanding these mechanisms is crucial for managing patient side effects and improving drug safety.

Purpose of the Study:

  • To investigate the neuropharmacological mechanisms of morphine-induced urinary retention in a rat model.
  • To determine the role of central opioid receptors in mediating the effects of morphine on bladder function.

Main Methods:

  • Anesthetized rats were used to observe bladder contractions during micturition.
  • Morphine was administered intravenously (i.v.), intracerebroventricularly (i.c.v.), and intrathecally (i.t.).
  • Naloxone, an opioid antagonist, was used to assess the involvement of opioid receptors.

Main Results:

  • Systemic and central administration of morphine prolonged the micturition interval and increased the micturition threshold.
  • Morphine inhibited bladder contraction in a dose-dependent manner, an effect reversed by naloxone.
  • Central administration (i.c.v. and i.t.) of morphine mimicked the effects of systemic administration, suggesting a central mechanism.

Conclusions:

  • Morphine-induced urinary retention is mediated by the inhibition of bladder function via opioid receptors in the supraspinal and spinal micturition centers.
  • These findings highlight the central nervous system's role in regulating micturition and the impact of opioids on this process.
  • Targeting central opioid pathways may offer new strategies for managing opioid-induced urinary dysfunction.